Table 1.
Physical characteristics of healthy individual (control) and rheumatoid arthritis (RA) patients included in the study.
Table 2.
Malondialdehyde, carbonyl, thiol group, tail length, FRAP, DPPH quenching, NOx, vitamin C, reduced glutathione, superoxide dismutase, catalase, glutathione reductase, glutathione S transferase in control and RA patients.
Fig 1.
Bar graph representation of data from DCFH-DA assay on lymphocytes of control and RA patients.
Fluorescence intensity was recorded at 530 nm using excitation wavelength of 485 nm. Results are mean ± S.D. (*p < 0.05 vs control).
Table 3.
Correlation between the ROS and various biochemical parameters in the RA patients.
Table 4.
Comparison of blood plasma and hemolysate parameters in RA patients sub-grouped according to the presence or absence of rheumatoid factor (RF- and RA+).
Fig 2.
Comparison of the DCF formed in control, RF- and RA+ RA patients.
(*p < 0.05 vs control).
Table 5.
Comparison of blood plasma and hemolysate parameters in RA patients sub-grouped according to the disease activity score (DAS).
Fig 3.
Comparison of the DCF formed in control, RA patients having DAS < 2.4 and DAS > 2.4.
(*p < 0.05 vs control).
Table 6.
Comparison of blood plasma and hemolysate parameters in RA patients sub-grouped according to the duration of the RA: newly diagnosed (ND), less than years (≤ 2 years) and between 2–5 years.
Fig 4.
Comparison of the DCF formed in control and RA patients sub-grouped according to the duration of RA: newly diagnosed (ND), less than or equal to 2 years (≤ 2 years) and between 2–5 years.
(*p < 0.05 vs control).